These include gene amplification leading to receptor overexpression, ligand overexpression (e.g., FGF7 and FGF10) driving autocrine or paracrine activation, bypass signaling that circumvents KIT and PDGFRA inhibition, and tumor microenvironmental interactions that promote tumor survival under therapeutic pressure. Here, PDGFRA is linked to neoplasm.